The simultaneous demonstrated anti-SDF-1 influence of NOX-A12 coupled with cell killing by TKI encouraged further studies exploring the ability of NOX-A12 to potentiate the effects of ABL inhibition in vivo, presumably by mobilizing BCR-ABL-positive leukemia cells out of bone marrow and into peripheral blood due to direct inhibition of SDF-1 and consequent blockade of its function in the stromal microenvironment as a chemoattractant. Here, ABL1 is linked to leukemia.